Overview
13th Annual Linda Morgante MS Nurse Leadership Program
Registration is closed for this activity.
The 13th Annual Linda Morgante MS Nurse Leadership Program will be held virtually on Saturday, September 17, 2022. This virtual meeting will help multiple sclerosis (MS) nurses refine their ability to translate evidence-based guidelines and emerging clinical research into practice. Linda Morgante worked tirelessly as an MS nurse and touched the lives of thousands of physicians, nurses and patients and their families. Linda inspired her students to strive for excellence in nursing and this program is named after her legacy. This program will feature didactic presentations, patient case mentoring pods, as well as office hours for faculty to reinforce key points, engage in Q&A, and discuss current challenges and frame opportunities in professional development.
This activity is intended for nurses and advanced practice clinicians who manage patients with multiple sclerosis (MS).
Mission Statement
The mission of the 13th Annual Linda Morgante MS Nurse Leadership Program is to improve the treatment of MS by providing an interactive training experience for MS nurses and by building a community among these nurses and today’s preeminent MS thought leaders.
The mission of the 13th Annual Linda Morgante MS Nurse Leadership Program is to improve the treatment of MS by providing an interactive training experience for MS nurses and by building a community among these nurses and today’s preeminent MS thought leaders.
Activity Purpose
The goal of the 13th Annual Linda Morgante MS Nurse Leadership Program is to provide nurses in MS with the opportunity to develop and refine their skill set within this therapeutic area.
Upon completion of this activity, participants will be able to:
• Apply evidence-based diagnostic and assessment approaches for evaluating disease activity in the brain and spinal cord to develop individualized treatment plans in patients with MS
• Evaluate the latest strategies to identify, assess, and manage emerging MS-related symptoms and disease modifying therapy (DMT)-related adverse events.
• Employ treat-to-target strategies and precision medicine to improve patient long-term outcomes
• Apply evidence-based diagnostic and assessment approaches for evaluating disease activity in the brain and spinal cord to develop individualized treatment plans in patients with MS
• Evaluate the latest strategies to identify, assess, and manage emerging MS-related symptoms and disease modifying therapy (DMT)-related adverse events.
• Employ treat-to-target strategies and precision medicine to improve patient long-term outcomes
| 10:00 AM* | Introduction & Welcome | Amy Perrin Ross, MSN, APN and Colleen Harris, MN, NP |
| 10:10 AM | Multiple Sclerosis Overview and Diagnosis | Aliza Ben-Zacharia, PhD, DNP, ANP-BC, FAAN |
| 11:00 AM | Expert Discussion #1 | Amy Perrin Ross, MSN, APN and Colleen Harris, MN, NP |
| 11:15 AM | Break | |
| 11:25 AM | Treatment Overview: Disease-Modifying Therapies and Relapse Management | Marie Namey, APRN, MSCN |
| 12:10 PM | Evolution of Precision Medicine: Treat-to-Target Approaches | Stephanie Agrella, PhD, ANP-BC, MSCN |
| 12:30 PM | Office Hours and Case Presentation #1 | Lynn McEwan, NP, MScN, CNNC, MSCN |
| 1:10 PM | Break | |
| 1:20 PM | Topics in MS Symptom Management | Constance Easterling, MSN, ARNP |
| 2:20 PM | Office Hours and Case Presentation #2 | Beverly Layton, RN, CCRC, MSCN and Michelle Keating, RN, MSCN |
| 3:00 PM | Lunch Break | |
| 3:15 PM | The Evolving Role of the MS Nurse: Multiple Sclerosis in the 21st Century | June Halper, MSN, APN-C, MSCN, FAAN |
| 3:30 PM | The Lived Experience of Multiple Sclerosis | Michelle Keating, RN, MSCN |
| 3:55 PM | Expert Discussion #2 | Amy Perrin Ross, MSN, APN and Colleen Harris, MN, NP |
| 4:10 PM | Conclusion | |
| 4:15 PM | Adjournment | |
| *Eastern Time Zone | ||
Sponsored by the Academy for Continued Healthcare Learning and Annenberg Center for Health Sciences at Eisenhower.
Supported by educational grants from Biogen, Bristol-Myers Squibb, and Novartis Pharmaceuticals Corporation.
Colleen Harris, MN, NP (Chair)
Nurse Practitioner Manager
University of Calgary MS Clinic
Calgary, Alberta, Canada
Amy Perrin Ross, MSN, APN, CNRN, MSCN (Chair)
Neuroscience Program Coordinator
Loyola University Chicago Medical Center
Maywood, Illinois
Stephanie Agrella, PhD, APRN, ANP-BC
Director of Clinical Services
MS Clinic of Central Texas Neurology
Round Rock, Texas
Nurse Practitioner Manager
University of Calgary MS Clinic
Calgary, Alberta, Canada
Amy Perrin Ross, MSN, APN, CNRN, MSCN (Chair)
Neuroscience Program Coordinator
Loyola University Chicago Medical Center
Maywood, Illinois
Stephanie Agrella, PhD, APRN, ANP-BC
Director of Clinical Services
MS Clinic of Central Texas Neurology
Round Rock, Texas
Aliza Ben-Zacharia, PhD, DNP, ANP-BC, FAAN, MSCN
Assistant Professor
Co-Director of the Research, EBP and QI Fellowship
Phillip School of Nursing, Mount Sinai and Hunter College Assistant Professor
New York, New York
Constance Easterling, MSN, APRN
Advanced Practice Registered Nurse
Research Consultant
MS Care Center
Neurological Services of Orlando
Orlando, Florida
June Halper, MSN, APN-C, MSCN, FAAN
Chief Executive Officer
Consortium of Multiple Sclerosis Centers and International Organization of Multiple Sclerosis Nurses
Hackensack, New Jersey
Michelle Keating, RN, MSCN
MS Nurse Consultant
President of MS Bright Spots of Hope
St. Louis, Missouri
Beverly Layton, RN, BSN
MS Nurse Consultant
Birmingham, Alabama
Lynn McEwan, NP, MScN
Nurse Practitioner MS Clinic
London, Ontario Canada
Marie Namey APRN, MSCN
Independent MS Nurse Consultant
Cleveland, Ohio
Annenberg Center and the Academy for Continued Healthcare Learning (ACHL) requires that all individuals with the potential to impact the content of an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
The following financial relationships have been provided:
Colleen Harris, MN, NP (Chair)
Consulting Agreements: Novartis; Sanofi Genzyme
Amy Perrin Ross, APN, MSN, CNRN, MSCN (Chair)
Consulting Agreements: Alexion; Biogen; BMS; EMD Serono; Genentech; Genzyme; Greenwich Biosciences; Horizon; Janssen; Merck; Roche; TG Therapeutics
Speaker’s Bureau: Alexion; BMS; Biogen; EMD Serono; Genentech; Genzyme; Horizon; Janssen
Stephanie Agrella, PhD, APRN, ANP-BC
Speaker’s Bureau: BMS; Biogen
Aliza Ben-Zacharia, PhD, DNP, ANP-BC, FAAN, MSCN
Publication grant: EMD Serono; Greenwich Biosciences
Consulting Agreements: Biogen
Advisory Board: Biogen; Genentech; Greenwich Biosciences; TG Therapeutics
Beverly Layton, RN, BSN
Consulting Agreements: Biogen; Novartis; Sanofi Genzyme
Speakers' Bureau: Sanofi Genzyme
Lynn McEwan, NP, MScN
Honorarium: Novartis; Roche; Sanofi Genzyme
The following faculty have no relevant financial relationships to disclose:
Cheryl Blaschuk, MSN
Constance Easterling, MSN, ARNP
June Halper, MSN, APN-C, MSCN, FAAN
Michelle Keating, RN, MSCN
Marie Namey APRN, MSCN
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Discussion of off-label agents for MS fatigue, neuropathic pain, MS spasticity, cerebellar dysfunction, and sexual dysfunction as well as discussion of investigational evobrutinib, fenebrutinib, remibrutinib, tolebrutinib, ublituximab, glatiramer acetate depot, vidofludimus calcium, CNM-Au8, T cell receptor peptide vaccine, arbaclofen, and nabiximols.
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporters. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantors.
This educational activity was planned and produced in accordance with the ANCC Accreditation Program. Recommendations involving clinical medicine in a continuing education (CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Clinicians should consult the current manufacturers’ prescribing information for these products. Annenberg and ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
To receive credit, participants are required to complete the pretest, participate in the live virtual activity and complete the posttest and evaluation. To receive credit, 80% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Katie Hacias at khacias@achlcme.org
In support of improving patient care, this activity has been planned and implemented by the Annenberg Center for Health Sciences at Eisenhower and the Academy for Continued Healthcare Learning. The Annenberg Center for Health Sciences at Eisenhower is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 5.50 ANCC contact hours which includes 1.50 pharmacology hours.
